Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Tables)

v3.21.2
Net Loss Per Share (Tables)
6 Months Ended
Jun. 30, 2021
Net Loss Per Share  
Schedule of reconciliation of net loss

For the Three Months Ended

For the Six Months Ended

June 30, 

June 30, 

    

2021

    

2020

    

2021

    

2020

Net loss

$

(6,620,576)

$

(4,536,818)

$

(14,243,716)

$

(10,910,238)

Net loss - Non-controlling interest

 

(77,379)

 

(82,388)

 

(168,341)

 

(163,702)

Net loss attributable to Heat Biologics, Inc.

$

(6,543,197)

$

(4,454,430)

$

(14,075,375)

$

(10,746,536)

Weighted-average common shares outstanding, basic and diluted

 

25,137,466

 

12,561,549

 

24,671,281

 

10,372,352

Net loss per share, basic and diluted

$

(0.26)

$

(0.35)

$

(0.57)

$

(1.04)

Schedule of potentially dilutive securities

    

2021

    

2020

Outstanding stock options

 

1,673,804

 

798,842

Restricted stock subject to forfeiture and restricted stock units

 

259,874

 

289,321

Outstanding common stock warrants

 

747,383

 

820,938